Skip to content

Released Aug 5, 2019, after the close

10-Q filed Aug 5, 2019, 36 days after period end · 0001144204-19-037687

Q2 2019 · 10-Q
Revenue$3.08M−4.3% vs Q2 2018−20.7% vs Q1 2019
Net Income-$18.50MN/M vs Q2 2018N/M vs Q1 2019
EPS Diluted-$0.72N/M vs Q2 2018N/M vs Q1 2019
Operating Income-$19,700,000N/M
Operating Cash Flowderived-$21,005,000N/M
Free Cash Flowderived-$21,056,000N/M
Margins · derived
Operating margin-639.6%+204.6 pt vs Q2 2018
Net margin-600.7%+232.3 pt vs Q2 2018

What the release said

The release

Same quarter

MetricQ2 2019Q2 2018Q2 2017Q2 2016
Revenue$3.08M$3.22M$2.36M—
Net Income-$18.50M-$26.81M-$13.60M-$10.15M
EPS Diluted-$0.72-$1.30-$780.00-$0.59

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR